Eli Lilly Stock On Fire: Up 15% With 6-Day Winning Streak
Eli Lilly (LLY) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 15% return. The company has gained about $111 Bil in value over the last 6 days, with its current market capitalization at about $842 Bil. The stock remains 22.2% above its value at the end of 2024. This compares with year-to-date returns of 14.3% for the S&P 500.
LLY provides innovative pharmaceuticals globally, including treatments for cancer, rheumatoid arthritis, and autoimmune diseases such as psoriasis and ankylosing spondylitis. After this rally, is LLY still a buy – or is it time to lock in gains? Deep dive with Buy or Sell LLY.
A single stock can be risky, but there is a huge value to a broader, diversified approach. Should you buy one stock you like or build a portfolio designed to win across cycles? Our numbers show that the Trefis High Quality Portfolio has turned stock-picking uncertainty into market-beating consistency. This portfolio is incorporated in the asset allocation strategy of Empirical Asset Management — a Boston area wealth manager and Trefis partner — whose asset allocation framework yielded positive returns during the 2008-09 period when the S&P lost more than 40%.
Comparing LLY Stock Returns With The S&P 500
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
The following table summarizes the return for LLY stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | LLY | S&P 500 |
|---|---|---|
| 1D | 1.3% | -1.1% |
| 6D (Current Streak) | 15.2% | -2.5% |
| 1M (21D) | 10.8% | -0.5% |
| 3M (63D) | 50.2% | 5.2% |
| YTD 2025 | 22.2% | 14.3% |
| 2024 | 33.3% | 23.3% |
| 2023 | 60.9% | 24.2% |
| 2022 | 34.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 35 S&P constituents with 3 days or more of consecutive gains and 61 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 20 |
| 4D | 8 | 28 |
| 5D | 1 | 5 |
| 6D | 3 | 2 |
| 7D or more | 0 | 6 |
| Total >=3 D | 35 | 61 |
Key Financials for Eli Lilly (LLY)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $34.1 Bil | $45.0 Bil |
| Operating Income | $10.8 Bil | $17.5 Bil |
| Net Income | $5.2 Bil | $10.6 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $12.7 Bil | $15.6 Bil |
| Operating Income | $5.4 Bil | $7.1 Bil |
| Net Income | $2.8 Bil | $5.7 Bil |
While LLY stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.